ONC BEONE MEDICINES LTD revenue, earnings and financials
For the quarter ended June 30, 2026, BEONE MEDICINES LTD reported revenue of $1.71B (up 29.6% from a year earlier), net income of $237M and diluted EPS of $0.16; over the last four quarters revenue was $6.13B and net income $656M; for the fiscal year ended December 2025 revenue was $5.34B, up 40.2% on the year before.
ONC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $5.34B, gross profit $4.67B, operating income $447M, net income $287M (margin 5.4%), EPS $0.19
- Fiscal year ended Dec 2024: revenue $3.81B, gross profit $3.22B, operating income −$568M, net income −$645M (margin -16.9%), EPS −$0.47
- Fiscal year ended Dec 2023: revenue $2.46B, gross profit $2.08B, operating income −$1.21B, net income −$882M (margin -35.9%), EPS −$0.65
- Fiscal year ended Dec 2022: revenue $1.42B, gross profit $1.13B, operating income −$1.79B, net income −$2.00B (margin -141.5%), EPS −$1.49
- Fiscal year ended Dec 2021: revenue $1.18B, gross profit $1.01B, operating income −$1.44B, net income −$1.46B (margin -123.9%), EPS −$1.21
ONC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.71B (up 29.6% year over year), net income $237M, EPS $0.16
- Quarter ended Mar 31, 2026: revenue $1.51B (up 35.5% year over year), net income $227M, EPS $0.15
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.50B (up 32.8% year over year), net income $66.5M, EPS $0.05
- Quarter ended Sep 30, 2025: revenue $1.41B (up 41.0% year over year), net income $125M, EPS $0.08
- Quarter ended Jun 30, 2025: revenue $1.32B (up 41.6% year over year), net income $94.3M, EPS $0.06
- Quarter ended Mar 31, 2025: revenue $1.12B (up 48.6% year over year), net income $1.27M, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.13B (up 77.8% year over year), net income −$152M, EPS −$0.10
- Quarter ended Sep 30, 2024: revenue $1.00B (up 28.2% year over year), net income −$121M, EPS −$0.09
- Quarter ended Jun 30, 2024: revenue $929M (up 56.1% year over year), net income −$120M, EPS −$0.09
- Quarter ended Mar 31, 2024: revenue $752M (up 67.9% year over year), net income −$251M, EPS −$0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue $634M (up 66.9% year over year), net income −$368M, EPS −$0.26
- Quarter ended Sep 30, 2023: revenue $781M (up 101.6% year over year), net income $215M, EPS $0.15
- Quarter ended Jun 30, 2023: revenue $595M (up 74.3% year over year), net income −$381M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue $448M (up 46.0% year over year), net income −$348M, EPS −$0.26
- Quarter ended Dec 31, 2022 (from the annual report): revenue $380M (up 77.6% year over year), net income −$445M, EPS −$0.33
- Quarter ended Sep 30, 2022: revenue $388M (up 87.8% year over year), net income −$558M, EPS −$0.41
- Quarter ended Jun 30, 2022: revenue $342M (up 127.7% year over year), net income −$566M, EPS −$0.42
- Quarter ended Mar 31, 2022: revenue $307M (down 49.4% year over year), net income −$435M, EPS −$0.33
- Quarter ended Dec 31, 2021 (from the annual report): revenue $214M, net income −$606M, EPS −$0.50
- Quarter ended Sep 30, 2021: revenue $206M, net income −$438M, EPS −$0.36
ONC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.13B, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$141M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.16B, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.50B, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.30B, share buybacks n/a
ONC balance sheet
- Jun 30, 2026: cash $5.10B, total assets $9.18B, total liabilities $4.00B, shareholders' equity $5.17B, long-term debt $882M
- Mar 31, 2026: cash $4.79B, total assets $8.55B, total liabilities $3.79B, shareholders' equity $4.76B, long-term debt $963M
- Dec 31, 2025: cash $4.55B, total assets $8.19B, total liabilities $3.83B, shareholders' equity $4.36B, long-term debt $962M
- Sep 30, 2025: cash $4.04B, total assets $7.63B, total liabilities $3.50B, shareholders' equity $4.13B
- Jun 30, 2025: cash $2.76B, total assets $6.30B, total liabilities $2.53B, shareholders' equity $3.77B, long-term debt $146M
- Mar 31, 2025: cash $2.52B, total assets $5.84B, total liabilities $2.34B, shareholders' equity $3.50B, long-term debt $160M
- Dec 31, 2024: cash $2.63B, total assets $5.92B, total liabilities $2.59B, shareholders' equity $3.33B, long-term debt $166M
- Sep 30, 2024: cash $2.70B, total assets $5.83B, total liabilities $2.39B, shareholders' equity $3.44B, long-term debt $188M
What is ONC's revenue?
BEONE MEDICINES LTD reported $6.13B of revenue over its last four quarters, through June 30, 2026.
Is ONC profitable?
Yes. BEONE MEDICINES LTD earned $656M over the last four quarters.
What is ONC's EPS?
Diluted earnings per share over the last four quarters were $0.44; $0.16 in the latest quarter.